Amal Therapeutics announced today that part of its recent research findings about a new type of recombinant protein cancer vaccines, will be available on-line on the Cancer Research website on Friday June 26, 2015. (Link)
The publication underlines the value of a novel immunotherapy class able to simultaneously inducing multi-epitopic immunity, T helper functions and immunologic memory. The article shows that vaccines tested are able to significantly prolonged survival in three robust tumor models. “The results published are demonstrating the proof of concept and showing the strength of Amal’s platform for the development of potent, safe and efficacious cancer vaccines”, said Dr. Derouazi, CEO of Amal Therapeutics. “Having the outcome of our work published in Cancer Research is a great success and a value recognition of the scientific approach taken since Amal’s incorporation in 2012”, added Dr. Derouazi.